Tonix Pharmaceuticals Holding CORP Form 4 insider transactions

Bradley Saenger, Chief Financial Officer of Tonix Pharmaceuticals Holding Corp., has acquired company shares through an employee stock purchase plan.

Tonix Pharmaceuticals Director Carolyn E. Taylor reports transactions involving the acquisition and disposition of common stock.

Director Richard Stillwell purchased 5,000 shares of Tonix Pharmaceuticals Holding Corp. common stock on June 8, 2026.

Tonix Pharmaceuticals CEO Seth Lederman purchased 5,000 shares of common stock in an open market transaction.

Director Richard Newcomb Stillwell was granted 22,700 stock options under the Tonix Pharmaceuticals 2026 Stock Incentive Plan.

Director Adeoye Y. Olukotun was granted 22,700 stock options under the Tonix Pharmaceuticals 2026 Stock Incentive Plan.

Director Margaret Smith Bell was granted 22,700 stock options in Tonix Pharmaceuticals under the 2026 Stock Incentive Plan.

Director James Randolph Hunter Jr. was granted 22,700 stock options in Tonix Pharmaceuticals Holding Corp. as part of the 2026 Stock Incentive Plan.

Director James Treco was granted 22,700 stock options under the Tonix Pharmaceuticals 2026 Stock Incentive Plan.

Director David L. Grange was granted 22,700 stock options under the Tonix Pharmaceuticals 2026 Stock Incentive Plan.

Director Richard H. Bagger was granted 22,700 stock options in Tonix Pharmaceuticals Holding Corp. on May 12, 2026.

Director Carolyn E. Taylor was granted 22,700 stock options under the Tonix Pharmaceuticals 2026 Stock Incentive Plan.

Tonix Pharmaceuticals CEO Seth Lederman purchased 5,000 shares of common stock at an average price of $12.62, signaling confidence.

Tonix Pharmaceuticals' Chief Operating Officer, Jessica Morris, was granted 78,023 stock options with varying exercise prices and a ten-year expiration.

Tonix Pharmaceuticals' Chief Financial Officer, Bradley Saenger, was granted 78,023 stock options with varying exercise prices and a 10-year expiration.

Tonix Pharmaceuticals' Chief Medical Officer, Gregory M. Sullivan, was granted 78,023 stock options with varying exercise prices and a future transaction date of February 24, 2026.

Tonix Pharmaceuticals' Chief Technology Officer, Siobhan Fogarty, was granted 78,023 stock options as part of her compensation package.

Tonix Pharmaceuticals CEO Seth Lederman was granted stock options for 269,007 shares of common stock with varying exercise prices and vesting schedules.

Tonix Pharmaceuticals Holding Corp. Director Carolyn E. Taylor acquired 418 shares of common stock at an average price of $36.03.

Tonix Pharmaceuticals Director James Treco reported a planned future purchase of 250 shares of common stock at $36 per share, effective August 20, 2025.

Tonix Pharmaceuticals Holding Corp. Director James Randolph Hunter Jr. was granted 7,740 stock options with an exercise price of $34.54, vesting on the date of the Company's 2026 annual meeting of stockholders.

Tonix Pharmaceuticals CEO Seth Lederman reports the acquisition of 4,000 shares of common stock at $21.55 per share on May 15, 2025.

James Treco, a director of Tonix Pharmaceuticals, reported the acquisition of stock options in a recent SEC filing.

Director Margaret Smith Bell acquired 10,000 stock options in Tonix Pharmaceuticals Holding Corp. on May 13, 2025, according to a Form 4 filing.

Carolyn E. Taylor, a director of Tonix Pharmaceuticals Holding Corp., reported the acquisition of stock options.

Director Richard H. Bagger acquired stock options in Tonix Pharmaceuticals Holding Corp. on May 13, 2025.

Director Richard Newcomb Stillwell received a stock option grant for 10,000 shares of Tonix Pharmaceuticals Holding Corp. on May 13, 2025.

Adeoye Y. Olukotun, a director at Tonix Pharmaceuticals, was granted a stock option for 10,000 shares on May 13, 2025.

Director David L. Grange acquired 10,000 stock options in Tonix Pharmaceuticals Holding Corp. on May 13, 2025.

A Tonix Pharmaceuticals director, Margaret Smith Bell, disposed of a fractional share of common stock due to an involuntary sale following a reverse stock split.